What is the appropriate hypertension management for a patient on Entresto (sacubitril/valsartan), metoprolol, and Lasix (furosemide) who still has uncontrolled blood pressure?

Add Spironolactone as Fourth-Line Agent

For a patient on Entresto (sacubitril/valsartan), metoprolol, and furosemide with uncontrolled hypertension, add low-dose spironolactone (12.5-25 mg daily) as the next step, provided eGFR ≥45 mL/min/1.73 m² and potassium is monitored closely. 1

Clinical Context and Current Regimen Analysis

This patient is already on:

• ARNi (Entresto) - provides RAS blockade plus neprilysin inhibition
• Beta-blocker (metoprolol) - likely for heart failure given Entresto use
• Loop diuretic (furosemide) - volume management

The current regimen lacks a calcium channel blocker (CCB) and a mineralocorticoid receptor antagonist (MRA), which are critical components of resistant hypertension management.

Stepwise Management Algorithm

Step 1: Confirm True Resistant Hypertension

Before adding medications, verify:

• Out-of-office BP confirmation using home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) 2
• Medication adherence - this is the most common cause of apparent resistance
• Proper BP measurement technique - appropriate cuff size, validated device
• Exclude white coat hypertension

Step 2: Optimize Current Regimen

• Maximize Entresto dose to target 97/103 mg twice daily if not already at this dose 3
• Assess volume status - if volume overloaded, optimize furosemide dosing rather than adding more agents 4
• Consider switching furosemide to chlorthalidone or indapamide (thiazide-like diuretics) if not volume overloaded, as these are more effective for BP control in resistant hypertension 1, 5

Step 3: Add Calcium Channel Blocker (If Not Present)

Before adding a fourth agent class, ensure the patient is on a dihydropyridine CCB (amlodipine 5-10 mg daily). The standard resistant hypertension regimen should include:

• RAS blocker (✓ Entresto provides this)
• CCB (appears missing)
• Thiazide-like diuretic (furosemide is a loop diuretic, not optimal)

Step 4: Add Spironolactone as Fourth-Line Agent

Once the above three-drug foundation is optimized, add spironolactone:

• Starting dose: 12.5-25 mg daily 1, 5
• Most effective fourth-line agent for resistant hypertension
• Superior to furosemide intensification - studies show spironolactone reduces systolic BP by ~24 mmHg vs. ~14 mmHg with furosemide in resistant hypertension 6

Critical monitoring requirements:

• Check potassium and creatinine at 2 weeks, then monthly for 3 months
• Hold if potassium >5.5 mEq/L
• Contraindicated if eGFR <45 mL/min/1.73 m² per current guidelines 5
• Higher risk in diabetics - monitor more frequently 6

Step 5: Alternative Fourth-Line Options

If spironolactone is contraindicated or not tolerated:

• Eplerenone (alternative MRA with less gynecomastia risk)
• Amiloride (potassium-sparing diuretic)
• Doxazosin (alpha-blocker)
• Bisoprolol (if not already on adequate beta-blockade) 1, 5

Important Considerations for Heart Failure Patients

Since this patient is on Entresto, they likely have heart failure with reduced ejection fraction (HFrEF). The 2024 ESC guidelines specifically state that in HFrEF patients, BP-lowering treatment should comprise:

• ACE inhibitor/ARB/ARNi (✓ Entresto)
• Beta-blocker (✓ metoprolol)
• Diuretic (✓ furosemide)
• MRA (missing - should add spironolactone) 1

Adding spironolactone serves dual purposes: BP control AND improved heart failure outcomes.

Lifestyle Reinforcement

Simultaneously reinforce:

• Sodium restriction to <2 g/day - particularly important as sacubitril/valsartan maintains efficacy regardless of salt intake 7, but sodium restriction enhances spironolactone effectiveness 1
• Limit alcohol
• Weight loss if BMI >25
• DASH diet adherence

When to Refer to Hypertension Specialist

Consider referral if:

• BP remains uncontrolled after adding spironolactone and optimizing doses
• Suspicion of secondary hypertension (young age, sudden onset, hypokalemia, resistant to 4+ drugs)
• eGFR <45 mL/min/1.73 m² requiring specialized MRA management
• Consideration for renal denervation in carefully selected patients with SBP 140-180 mmHg despite optimal 3-4 drug therapy 1, 5

Common Pitfalls to Avoid

• Don't add multiple agents simultaneously - titrate one drug at a time to assess individual response
• Don't use loop diuretics as primary BP agents - switch to thiazide-like diuretics unless volume overload present
• Don't forget to check adherence - this accounts for most "resistant" hypertension cases
• Don't add spironolactone without potassium monitoring - hyperkalemia risk is real, especially with Entresto (ARNi) on board
• Don't overlook secondary causes - particularly primary aldosteronism if hypokalemic